SCHEMBL1151222

SCHEMBL1151222

CN(C)S(=O)(=O)c1cc(F)ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 3/20 0.43
KCNJ5 P48544 3/20 0.43
KCNJ3 P48549 3/20 0.43
SERPINE1 P05121 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MCL1 Q07820 1/20 0.40
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15964234 0.79 TRPA1 (0.45) KCNJ6KCNJ5KCNJ3SERPINE1MCL1
SCHEMBL1151540 0.79 KCNJ6 (0.57) KCNJ6KCNJ5KCNJ3MEN1KMT2A
SCHEMBL22396701 0.79 CA3 (0.41) KDM4ECA3CA6CA5ACA9
SCHEMBL2062378 0.78 ALDH1A1 (0.51) KCNJ6KCNJ5KCNJ3KDM4ECA6
SCHEMBL1913490 0.78 CA1 (0.44) SERPINE1KDM4EMCL1CA9MEN1
SCHEMBL644251 0.77 DPP4 (0.44) KCNJ6KCNJ5KCNJ3KDM4EPSEN1
SCHEMBL13512891 0.76 KDM4E (0.46) KCNJ6KCNJ5KCNJ3KDM4EKMT2A
SCHEMBL6359929 0.76 HSD17B10 (0.49) KDM4EMCL1CA3CA6CA5A
SCHEMBL10838459 0.76 CA9 (0.46) CA3CA6CA5ACA9CA14
SCHEMBL14456671 0.75 KDM4E (0.42) KCNJ6KCNJ5KCNJ3KDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291377-B1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2015-02-18 EP disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 KCNJ6 2117/4885KCNJ5 1567/4885KCNJ3 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.